VIVUS reports product revenues of $8.5M from sale of MUSE in fourth-quarter 2009

BeaconEquity.com announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision. 

The full report is available at: http://www.beaconequity.com/i/VVUS

Get our alerts BEFORE the rest of the market.  Follow us on Twitter: https://twitter.com/BeaconEquity

VIVUS Inc. (VVUS) is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company's product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. One of these investigational products, Qnexa, is in phase III clinical trials for obesity and in phase II clinical trials for diabetes.  

Message Board Search for VVUS: http://www.boardcentral.com/boards/VVUS

In the report, the analyst notes:

"Product revenues from the sale of MUSE in the fourth quarter of 2009 were $8.5 million as compared to $7.8 million in the fourth quarter of 2008, primarily due to a modest increase in shipments and an increase in domestic prices in 2009. Total revenue for the fourth quarter of 2009 was $8.6 million, as compared to $28.8 million for the fourth quarter of 2008.

"VVUS recently announced the issuance of three additional patents by the U.S. Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents are the second, third and fourth patents to be granted in a series of patent applications VVUS has filed that are directed to the Qnexa product and methods of using Qnexa in various therapeutic applications."